Study Subjects
The Northwestern Medicine Enterprise Data Warehouse was queried to identify all patients who were prescribed ibrutinib between July 2012 and July 2016, and received primary oncologic care at our institution. Patients were aged 18 to 90 years old, and all patients with a prior history of AF were excluded. One hundred sixty-nine patients were initially identified. Of these patients, those who had a transthoracic echocardiogram prior to initiation of ibrutinib therapy were included, yielding a total 75 patients. Nine patients were excluded because echocardiographic images were not available for review on Northwestern software, yielding a total 66 patients.
Demographic information was collected through a retrospective chart review of each patient’s electronic medical record, including gender, race, age of patient at initiation of ibrutinib, and body mass index (BMI). Comorbidities included hypertension (HTN), hyperlipidemia (HLD), diabetes (DM), coronary artery disease (CAD) and clinical history of heart failure (HF) prior to initiation of ibrutinib. Information regarding ibrutinib dose, length of follow up, rates of CVA among patients who developed IRAF and rates of anticoagulant and antiplatelet use for patients with IRAF were also noted. Duration of follow up was defined as either time to development of AF, time until last follow up, or time until patient death. The Northwestern University institutional review board approved this study.